Investor Update

Basel, 8 December 2011

Roche conference call for investors and analysts from SABCS 2011

CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer

Friday, 9 December 2011, San Antonio TX, USA

We kindly invite investors and analysts to participate in a conference call that will be held during the San Antonio Breast Cancer Symposium taking place from 6-10 December in San Antonio.

On the call, Roche will discuss new data from CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer. Further, Roche will provide an overall update on development plans for pertuzumab and the HER2 franchise. The presentation will be followed by a Q&A session.

The conference call will take place on:

Friday, 9 December 2011

Investors and analysts are invited to join the conference call either by live audio webcast or by telephone.

Live audio webcast

The live conference call can be accessed via http://ir.roche.com. Following the event, an MP3 file will be made available for download.

Phone conference call

The live conference call can be accessed using the following dial-in numbers:

Please dial in to the conference call 10 – 15 minutes before the call is scheduled to start.

A replay of the conference call will be available one hour after the conference call and then for 48 hours. The replay can be accessed using the following dial-in numbers:

Enter the ID 13530 followed by the # sign.

At the time of the conference call, the accompanying presentation will be available from the IR website at http://ir.roche.com.